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doi:10.1016/j.jtcvs.2004.04.007Background: Locally delivered angiogenic growth factors and cell implantation
have been proposed for patients with myocardial infarcts without a possibility of
percutaneous or surgical revascularization. The goal of this study was to
compare the effects of these techniques in an experimental model of myocardial
infarct.
Methods: Left ventricular myocardial infarction was created in 27 sheep by ligation
of 2 coronary arteries. Three weeks after creation of the infarct, animals were
randomized into 4 groups. In group 1, sheep received a culture medium injection to
the infarct area (control group); group 2 underwent autologous myoblast implanta-
tion; group 3 received vascular endothelial growth factor; and group 4 received
injection of both vascular endothelial growth factor and myoblasts. Evaluation
included serum troponin IC levels, echocardiography (2-dimensional and color
kinesis), and immunohistologic studies for quantitative analysis of capillaries (3
months after surgery).
Results: Four animals died of refractory ventricular fibrillation during myocardial
infarction; 2 died after surgery because of stroke and 2 because of infections. Serum
troponin increased to 45.6  4.7 ng/mL at postinfarction day 2. Echocardiography
at 3 months showed a significant limitation of left ventricular dilation in the cell
group (57  11.1 mL) and in the cell plus vascular endothelial growth factor group
(58.6  6.6 mL: control group, 74.4  11.2 mL; vascular endothelial growth factor
group, 68.1  3.4 mL). Color kinesis echography showed important improvements
of regional fractional area change in the cell group (from 13.6%  0.8% to 21.1%
 1.5%) and in the cell plus vascular endothelial growth factor group (from 12.8%
 0.9% to 18.7%  2.3%). The number of capillaries increased in the peri-infarct
region of the vascular endothelial growth factor group (1036  75: control group,
785  31; cell group, 830  75; cell plus vascular endothelial growth factor group,
831  83).
Conclusions: In the cell therapy groups, regional ventricular contractility improved
and heart dilatation was limited compared with either vascular endothelial growth
factor or control; thus, postischemic remodeling was reduced. Angiogenesis was
demonstrated in the vascular endothelial growth factor group, without improvement
of ventricular function and remodeling. To improve local conditions for cell sur-
vival, further studies are warranted on prevascularization of myocardial scars with
angiogenic therapy.
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CSPAvariety of novel angiogenic therapies inthe form of proteins, cells, and genes arebeing evaluated as adjuncts to bypassgrafting or as sole therapy for patientswho are not candidates for coronary ar-tery surgery. The goal of these interven-
tions is to induce angiogenesis and increase perfusion to
ischemic regions of the heart that cannot be adequately
revascularized.1-9
Another approach for myocardial regeneration consists
of the implantation of myogenic cultured cells into infarcted
myocardium. Cell engraftment has been detected in histo-
logic studies,10-12 but high cell mortality and cells embed-
ded within fibrosis without neovascularization have been
observed. This represents a risk for micro re-entry circuits
that can generate ectopic ventricular arrhythmias.13-17
The encouraging preliminary functional results of cellu-
lar cardiomyoplasty have probably been facilitated by the
coronary artery bypass grafting or angioplasty procedures
performed simultaneously with cell transplantation.18-21
Cell survival after implantation in infarcted myocardium is
still a challenge, because the oxygen and nutrient supply are
limited within the scar.
The goal of this study was to investigate the effects of
angiogenic growth factors associated or not with cellular
myogenic therapy in myocardial infarcts. We evaluated
myocardial function, ventricular remodeling, and angiogen-
esis.
Materials and Methods
Experimental Animals
In 27 female Rambouillet sheep weighing 21 to 34 kg (mean, 30
 3.5 kg), a left ventricular (LV) myocardial infarct was surgically
created. Three weeks after coronary artery ligation, 4 different
treatments were conducted. In group 1 (control group), sheep
received in the infarcted area the injection of cell culture medium
(Ham’s F12) with fetal calf serum. In group 2, autologous cultured
myoblasts were implanted. In group 3, 100 g of vascular endo-
thelial growth factor (VEGF; isoform 165) was injected. In group
4, the myoblasts were associated with VEGF and injected simul-
taneously into the scar. All procedures were approved by the
French National Institute of Health and Medical Research.
Anesthetic and Postoperative Management
Premedication of acepromazine 150 mg (Vetranquil) was injected
intramuscularly. Thirty minutes later, propofol (Diprivan) was
injected intravenously into the left jugular vein at a concentration
of 6 mg/kg. The intubation was performed with an endotracheal
probe (No. 7). Ventilation was ensured with a Siemens 900C
respirator (Siemens AG, Munich, Germany) by use of the follow-
ing parameters: a volume of 10 mL/kg, a frequency of 24 breaths/
min, and an inspired oxygen fraction of 60%. Anesthesia was
maintained by inhalation of isoflurane 1% to 2%. Postoperative
management of the sheep consisted of cefazolin injected intramus-
cularly at 1 g per day over 5 days.
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A 1-cm3 skeletal muscle fragment was explanted from the left
posterior femoral biceps of each sheep under sterile conditions.
The biopsy tissue was kept in Hanks balanced salt solution (Life
Technologies, Rockville, Md) at 4°C until the cell culture was
started.
Via a left thoracotomy, the ligation of the distal homonymous
(equivalent to human left anterior descending) and second diago-
nal coronary arteries produced a constant transmural infarct.22,23
To reduce the risk of ventricular fibrillation, lidocaine 1% (2 mg ·
kg1 · h1) was administered IV during the entire surgical proce-
dure. Thereafter, a drain was placed in the pleural cavity, and the
thoracic wall was closed. The drain was removed as soon as the
sheep started spontaneous respiration.
The severity of the myocardial injury was expressed in cardiac
troponin IC serum levels and was measured 48 hours after infarc-
tion. The quantitative determination was assessed with a cardiac
troponin IC fluorometric enzyme immunoassay (Stratus; Dade
Behring, Deerfield, Ill).
Satellite Cell Isolation and Culture
Skeletal myoblasts obtained from autologous muscle biopsy sam-
ples were isolated, purified, and cultured as previously described.12
In brief, the cells were cultured for 3 weeks in Ham’s F12 medium
containing 20% fetal calf serum (FCS) and 1% penicillin/strepto-
mycin. To reduce the number of fibroblasts and achieve a pure
myoblast culture, a preplating step was applied on the first passage.
The preplating technique was based on the quicker attachment of
fibroblasts compared with satellite cells. At 3 weeks, the cultured
myoblasts were detached from the cell culture dish with 0.25%
trypsin-ethylenediaminetetraacetic acid. After centrifugation at
300g for 5 minutes, 70 million cells were resuspended in 1 mL of
culture medium and used for each transplantation.
Evaluation of VEGF in Cultured Cells
From human umbilical cords, vascular endothelial cells were iso-
lated and cultured in M199 culture medium (BioWhittaker, Ver-
vier, Belgium) containing 20% FCS. After 1 week, 100,000 en-
dothelial cells were obtained and grown in the presence of 50 g
of VEGF (isoform 165; Laboratory of Molecular Biology, CNRS,
University of Toulouse, Toulouse, France). A week later, the final
cell number was calculated and compared with a control group
cultured without growth factors. There were 900,000 endothelial
cells in the cultures that included VEGF versus 550,000 cells in the
control group, thus confirming the efficacy of VEGF protein ac-
tivity.
Cell Injection
After a 3-week in vitro expansion period, via a median sternotomy,
the cell suspension and VEGF were injected into the center and the
border of the scar by using an insulin syringe and a retrobulbar
ophthalmic needle (25 gauge 40 mm). The same volume (1 mL)
of culture medium was injected in group 1. A suspension contain-
ing both myoblasts and VEGF was injected in group 4. The
injected area was identified with 2 single sutures associated with
metal ligating clips.
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PEvaluation of Ventricular Function
Echocardiography with color kinesis software (Sonos 5500;
Hewlett-Packard, Palo Alto, Calif) was performed at cell implan-
tation or at control medium and VEGF injections, 3 weeks after
infarction, and at death (3 months after surgery) with the aid of a
7-MHz transducer in the epicardial position. End-systolic frames
were used for analysis to obtain quantitative information because
they contain the entire spatial and temporal histories of the systolic
endocardial excursion.24-26 Color-encoded images obtained from
the short-axis and apical 4-chamber views were automatically
divided into wedge-shaped segments with the custom-designed
software. This segmentation schema was used to minimize the
variability caused by individual differences in LV orientation at
end-systole and therefore facilitate intersubject comparisons. Re-
gional wall motion was then assessed by computing the pixel
counts in each LV segment. The segments were normalized by the
corresponding regional end-systolic area to take into account in-
tersegmental geometric differences and quantify the regional frac-
tional area change (RFAC) for each consecutive frame. In com-
parison with the regional wall motion, the global cardiac function
was measured at the same time points in the 2-dimensional mode.
The global parameters included the LV end-diastolic and end-
systolic diameters, the shortening fraction, the end-diastolic and
systolic volumes, and the ejection fraction. The ejection fraction
and shortening were calculated by the Teicholz method and were
based on the LV end-systolic and end-diastolic diameters.
Histology and Immunohistochemistry
All sheep were put to death 3 months after cell or VEGF therapy.
The site of myocardial injury was identified and dissected. Four to
5 specimens were used, and each of these was cut into 2 pieces.
The first one was fixed in 10% formol, embedded in paraffin, and
sectioned to yield 10-m-thick slices. The sections were stained
with hematoxylin and eosin. The second piece of each specimen
was frozen in liquid nitrogen–cooled isopentane. Frozen biopsy
tissue was stored at 80°C until it was processed on a cryostat.
When cells were observed in the infarct sections, they were tested
with fast myosin heavy chain antibody (MY-32; Sigma Aldrich,
St. Louis, Mo), which is specific for the skeletal isoform of adult
fast myosin heavy chain.
For immunohistochemical studies, 5-m-thick sections of fro-
zen tissues were fixed for 10 minutes in cold acetone, and endog-
enous avidin and biotin sites were blocked (Dako, Glostrup, Den-
mark). Samples were incubated with the myosin heavy chain
antibodies (1:300) in 0.1% FCS for 1 hour, followed by incubation
with biotinyl anti-mouse immunoglobulin (1:200) (Vector Labo-
ratories, Burlingame, Calif), and were finally incubated with
streptavidin-cyanine 2 (Amersham Biosciences, Buckinghamshire,
United Kingdom) 1:800 in phosphate-buffered saline for 30 min-
utes. The slides were then mounted with the Immuno-mount sys-
tem (Thermo Shandon, Runcorn, United Kingdom) and studied
with an inverted fluorescent microscope (Nikon Eclipse TE300;
Nikon Inc, Melville, NY).
Vascular endothelial cells were identified by using antibodies
against von Willebrand factor VIII–related antigen (Dako). Sub-
sequent morphometric analyses with optic microscopy permitted
the evaluation of capillary density by the count of vessels stained
The Journal of Thoraciby the antibody on an average of 100 fields for each animal (20
fields for each specimen).
Statistical Methods
Results are reported as percentage or mean  SD. A paired or
unpaired Student t test was used to compare the groups when
needed. A 1-way analysis of variance was used when more than 2
groups were present. When indicated, a Student-Newman-Keuls
multiple comparison test was used as a post hoc test.
Results
Myocardial Infarction Creation
Even though antiarrhythmic drugs were administered during
the operation, ventricular fibrillation was the major compli-
cation: it was present in 9 cases and lethal in 4 animals. Two
sheep died after surgery because of stroke and 2 because of
infections. At 3 months, the number of surviving animals in
each group was as follows: group 1, n  5; group 2, n  6;
group 3, n  4; group 4, n  4.
The average serum level of cardiac troponin 2 days after
infarction was 45  4 ng/mL. Macroscopically at 3 weeks,
a local area of necrosis was consistently observed in the
apex and anterolateral LV wall of all animals. After 3
months, the area of necrosis had developed in transmural
scars measuring 695  70 mm2 in the control group, 654 
51 mm2 in the cell group, 641  20 mm2 in the VEGF
group, and 681 35 mm2 in the cell plus VEGF group. The
mean ventricular wall thickness in the central part of the
lesion was 2.60  0.17 mm, without important differences
between the control and treated groups.
Echocardiography
The results of the 2-dimensional echocardiographic assess-
ment for global cardiac function are summarized in Tables
1 and 2. The measurements were performed 3 and 12 weeks
after myocardial injury. With a paired Student t test, the 2
time points were compared within the cell-treated groups. A
statistical difference was not found for LV ejection fraction,
but the difference was significant for LV end-diastolic vol-
ume; there was significant ventricular dilation in the control
and VEGF groups. Otherwise, in the cell-treated groups, LV
volume was stable at 3 months, passing from 55.6 4.6 mL
at 3 weeks after infarction to 57  11.1 mL and from 55.7
 5.3 mL to 58.6  6.6 mL in groups 2 and 4, respectively.
No significant differences were observed between groups 2
and 4.
Echocardiography with color kinesis software showed no
important differences at baseline among the 4 groups. At 12
weeks, the percentage of end-systolic area of the regional
LV wall motion, expressed as RFAC, showed a significant
increase in regional function in cell-transplanted groups,
from 13.6%  0.8% before cell transplantation to 21.1% 
1.5% at 3 months and from 12.8%  0.9% before versus
18.7%  2.3% after cell plus VEGF therapy. The RFAC in
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CSPgroups 1 and 3 (without cell transplantation) did not in-
crease: it was 11.6%  0.8% at the moment of medium
injection versus 10.5%  1.7% at the 3-month follow-up,
and it was 17.5%  1.3% before VEGF injection versus
11.9%  0.7% at 3 months. No significant differences were
observed between groups 2 and 4. The color-encoded im-
ages, using backscatter, identified the pixel transition from
tissue to blood, which were updated on a frame-by-frame
basis, resulting in color overlays.
Identification of Myoblasts
By histologic analysis with hematoxylin and eosin stain, in
all groups we found infarcted areas characterized by the
replacement of healthy myocardium by adipose and fibrous
tissue, as well as a low inflammatory response. Postinfarc-
tion myocardial scars in sheep are predominantly infiltrated
by adipose tissue. By immunohistochemical analysis, sec-
tions from 7 of 10 sheep treated with cells were positively
stained with myosin heavy chain (the skeletal isoform of
adult fast myosin heavy chain), and satellite cells were
detected. This antibody did not react with healthy or isch-
emic cardiac sections, nor did it stain the type 1 fibers (slow
twitch) of the skeletal muscle sections. Furthermore, in 4 of
these animals, elongated skeletal muscle cells structures
were observed that resembled multinucleated myotubes and
in some sections presented a fibrillar configuration (Figure
1). No skeletal muscle cells were found in the healthy
TABLE 1. Echocardiographic studies after myocardial infa
Group
LVEDV (mL) LVESV (m
3 wk 12 wk 3 wk
Control 52.4 2.1 74.4 11.2 31.3 2.8
Cells 55.6 4.6 57 11.1 32.8 3.1
VEGF 53.8 1.6 68.1 3.4 31.3 1.2
Cells  VEGF 55.7 5.3 58.6 6.6 34.5 5.4
Data are means  1 SD. LVEDV, Left ventricular end-diastolic volume; LV
fractional area change; VEGF, vascular endothelial growth factor.
TABLE 2. Echocardiographic results: Analysis of variance
DF
Sum of
squares
Mean
square
EF (%) difference
Group 3 20,414 6,805
Residual 15 382,533 25,502
LVEDV (mL) difference
Group 3 1439,825 479,942
Residual 15 1070,579 71,372
LVESV (mL) difference
Group 3 602,839 200,946
Residual 15 639,601 42,640
DF, Degrees of freedom; EF, ejection fraction; LVEDV, left ventricular endmyocardium.
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Some degree of angiogenesis developed at the periphery of
the infarct region and not in the center of the scar. An
important increase in the number of capillaries (P  .0443)
was observed in the group treated with protein-based
growth factors. The mean number of capillaries in the
peri-infarct area of the VEGF group was 1036 75 (control
group, 785  31; cell group, 830  75; cell plus VEGF
group, 831 83). Significant angiogenesis was not detected
in the center of the scar, and the number of capillaries was
144  64 in the control group, 278  82 in the cell group,
218  79 in the VEGF group, and 254  87 in the cell plus
VEGF group (Figure 2).
Discussion
Coronary artery bypass grafting is the most common cardiac
operation in Europe and the United States; however, in 20%
of patients, it is not possible to achieve complete revascu-
larization. Cell transplantation, growth factors, and gene
therapy represent emerging biologic treatments conceived
to improve myocardial viability in ischemic heart failure. A
biologic regenerative approach to patients at risk of conges-
tive heart failure may be effective for reversing the post-
ischemic remodeling process, which is characterized by
progressive expansion of the initial infarct area and dilation
of the LV lumen, with cardiomyocyte replacement by fi-
n
EF (%) RFAC (%) color kinesis
wk 3 wk 12 wk 3 wk 12 wk
5.6 40.2 5.9 39.8 3.6 11.6 0.8 10.5 1.7
8.8 42.7 2 43.3 4.3 13.6 0.8 21.1 1.5
4.9 41.8 3.1 43.3 4.1 17.5 1.3 11.9 0.7
5.9 38.3 5.1 40.8 9.6 12.8 0.9 18.7 2.3
left ventricular end-systolic volume; EF, ejection fraction; RFAC, regional
F value P value Lambda Power
0.267 .8483 0.800 0.089
6,725 .0043 20,174 0.931
4,713 .0164 14,138 0.802
olic volume; LVESV, left ventricular end-systolic volume.rctio
L)
12
44.6
32.8
38.3
34.6
ESV,brous tissue deposition in the ventricular wall.
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PThe goal of this study was to compare the effects of
myoblast implantation and the injection of VEGF in a
Figure 1. Histoimmunologic studies at 3 months of the i
in multinucleated myotubes and presenting in some se
to fast-twitch skeletal myosin (original magnification,
Figure 2. Histologic assessment of sheep myocardial
scar is penetrated by grafted myoblasts (blue) and neov
the upper and lower borders of the figure. Myogenesis
antibodies. Angiogenesis (red stain) was evaluated
Willebrand factor VIII antibody (double-stain techniqumodel of myocardial infarct in large animals. Our results
The Journal of Thoracishowed that myogenic cell transplantation, associated or not
with angiogenic growth factors, improved regional myocar-
t region, showing isolated grafted myoblasts organized
s a fibrillar configuration. Stain with MY-32 antibody
).
ction after treatment with cells and VEGF. The infarct
ls (red) ; healthy myocardial tissue can be observed in
stain) was identified by using fast myosin heavy chain
he identification of endothelial cells with anti–von
iginal magnification, 200).nfarc
ctioninfar
esse
(blue
by tdial contractility and limited LV chamber remodeling. In
c and Cardiovascular Surgery ● Volume 128, Number 2 249
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CSPcontrast, no functional benefit was shown in the group
treated with VEGF. Similar results have been observed in
another experimental study in which intramyocardial and
intracoronary delivery of basic fibroblast growth factor in
porcine hibernating myocardium resulted in improved per-
fusion without functional advantages.27 It can be postulated
that the administration of VEGF 3 weeks after creation of
the infarct model could be considered too late to achieve
functional benefits or that this therapy may require long
time periods to develop. Probably postimplant cell mortality
starts too soon, ie, before the development of neovascular-
ization. For this reason, angiogenic growth factors could be
delivered into myocardial infarct areas several days before
cell transplantation to first improve local perfusion condi-
tions for cell survival (preconditioning).
Angiogenesis was observed only in animals treated with
VEGF alone (ie, not when associated with myoblast trans-
plantation). Similar results were observed in human patho-
logic studies after myoblast implantation, confirming the
lack of angiogenesis.13,14 Simultaneous delivery of VEGF
and cells did not show angiogenic effects. This finding is
unexpected and is currently unexplained. It could be hy-
pothesized that the combination of both products at the
moment of injection induced some degree of chemical or
biologic inactivation of the VEGF properties or that the
growth factor effect can be reduced or masked by the
inflammatory reaction generated by the injected cells and
bovine culture medium (FCS).
The mechanism of the beneficial effects of cellular car-
diomyoplasty achieved in preclinical studies and clinical
trials needs to be elucidated. It was suggested that cell
transplantation stabilizes the infarct region, induces angio-
genesis, and modifies the response of the remaining myo-
cardium to the infarct. Angiogenesis seems to be obtained
when bone marrow–derived cells are implanted for myo-
cardial regeneration.12 The effects of cell transplantation
seem to be related to a profound biologic response to cell
engraftment that influences both regional and global remod-
eling of the heart.10-12,28 These effects on the ischemic
failing heart can be limited by the local environment, be-
cause the fibrotic area in and around infarct regions is not
adequate for cells to survive in: they are exposed to poor
conditions in which certain requirements cannot be ade-
quately supplied because the oxygen and nutrients supply
are reduced within the scar.
In our study, histologic demonstration of cell engraft-
ment was achieved in 70% of cases. The histologic studies
were performed at 3 months in selected areas of the LV and
not in the whole heart (as is done for small animals). It is
possible that the selection of heart tissue samples for mi-
croscopic examination did not correspond exactly with the
cell injection areas, and there were difficulties related to the
fact that the autopsies were performed after 2 cardiac oper-
250 The Journal of Thoracic and Cardiovascular Surgery ● Auguations (creation of myocardial infarction and VEGF or cell
implantation). Furthermore, the nonobservation of cells in 3
sheep could be because we used specific fast type myosin
heavy chain antibodies for identification of skeletal myo-
blasts in the myocardium. However, the implanted cells
could have changed from a fast type to a slow myosin type
after a 3-month implantation in a beating heart, as observed
in previous studies,11 or this could occur simply because
there were slow myosin heavy chain–type myoblasts in the
original skeletal muscle biopsy.
Therapeutic angiogenesis is a strategy designed to am-
plify the native angiogenic process and enhance the reper-
fusion of ischemic tissues. There are 3 approaches to induce
angiogenesis and vasculogenesis: proteins, cells, and gene
therapy. The administration of growth factors in the form of
proteins presents risks of systemic effects, inducing prob-
lematic angiogenesis in the retina, expanding atheroscle-
rotic lesions, or potentiating growth and metastasis of occult
tumors. However, these deleterious effects have not been
observed in current clinical trials, in which therapeutic
angiogenesis seems to provide improvement in angina and
exercise treadmill test results in patients with stable exer-
tional angina.29,30 Transplanted endothelial cells removed
from the intima of arteries and veins can stimulate angio-
genesis and can be incorporated into the new vessels, in-
creasing regional perfusion in myocardial scar tissue.4 Bone
marrow from adult humans contains endothelial precursors
with phenotypic and functional characteristics of embryonic
hemangioblasts that can be used to directly induce new
blood vessel formation in the infarct bed (vasculogenesis)
and to induce proliferation of preexisting vasculature (an-
giogenesis) after myocardial infarction or in chronic limb
ischemia.31-34 Gene therapy consists of the introduction of
new genetic material into somatic cells to synthesize pro-
teins that are missing, defective, or desired for specific
therapeutic purposes.35-37 Growth factor gene therapy pre-
sents risks related to stability, unregulated expression, and
adverse responses to transfection vectors.9,38
To enhance the effects of cellular cardiomyoplasty, he-
patocyte growth factor has been recently proposed by Miya-
gawa and associates39 as a combined therapy. The authors
hypothesized that transfection of the gene for human hepa-
tocyte growth factor combined with cellular cardiomyo-
plasty might regenerate the impaired myocardium. Prelim-
inary results are encouraging, and the main effect seems to
be the reduction of fibrosis in the infarct scar. In another
article, Sakakibara and associates40 showed prevasculariza-
tion of myocardial infarcts with gelatin microspheres con-
taining basic fibroblast growth factor to enhance the effects
of cardiomyocyte transplantation. According to the studies
of von Lewinski and colleagues41 and Lai and colleagues,42
insulin-like growth factor 1 seems to be a promising thera-
2peutic alternative because it exerts Ca -dependent positive
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Pinotropic effects in failing human myocardium. Angiogenic
and myogenic growth factors (VEGF, basic fibroblast
growth factor, and RGTA [ReGeneraTing Agent]) have
been evaluated by our group in a cardiomyoplasty model,
and they resulted in improved vascularization and trophicity
of skeletal muscles.43
As suggested by our experimental results and the inter-
national literature, skeletal myoblasts and bone marrow
cells that engraft in the infarct region alter the elastic prop-
erties of the transplantation site, limit infarct expansion, and
prevent the ventricular dilation and remodeling that results
in congestive heart failure.44,45 Our histologic studies and
clinical pathologic data13,14 could not demonstrate any an-
giogenic effects of myoblast grafting. To improve the hy-
poxic myocardial environment, prevascularization of myo-
cardial infarcts could be considered before cellular
cardiomyoplasty. This combined therapeutic approach
could be facilitated by catheter-based interventional cardi-
ology procedures.46 It can be postulated that staged angio-
genic and myogenic therapeutic procedures may be benefi-
cial for myocardial regeneration. Further studies are
warranted to confirm the efficacy of such a 2-stage strategy.
Many questions concerning the mechanisms of myocar-
dial regeneration will probably be answered by upcoming
investigations. It is to be hoped that the fields of cell
therapy, tissue engineering, growth factors, and gene ther-
apy might mutually benefit from their respective advances.
These fields must be considered as complementary, with
combined strategies. The ultimate goal is the improvement
of the outcome of patients with severe ischemic and non-
ischemic myocardial diseases.47
This study was performed in an infarct model that re-
sulted in 30% sheep mortality. Therefore, the numbers of
animals in the groups were reduced at the moment of
evaluation. The absence of differences observed between
groups either can be due to insufficient power of our anal-
ysis because of the small number of animals or can be due
to a real absence of treatment effects at the 3-month follow-
up. These therapies may require longer periods to develop.
The number of cells engrafted in the myocardium should
represent important information for evaluating the combi-
nation of growth factors with cellular therapy. Simultaneous
or successive applications of these approaches deserve ad-
ditional consideration. These aspects were not assessed in
our study and require further investigation.
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Discussion
Dr Frank W. Sellke (Boston, Mass). Which isoform of VEGF
did you administer, and exactly where did you inject it: into the
infarct area or the border area?
Dr Chachques. We administered VEGF isoform 165. We
performed 70% of our injections in the peri-infarct area (in the
intermediate area) and 30% in the middle of the scar. We have
demonstrated in previous studies that the cell survival is better in
the intermediate area. We injected the cells together with the
growth factors that were included in the injection medium. This
implantation was made with a 25-gauge  40-mm retrobulbar
ophthalmology needle.
Dr Sellke. Did you really think that the VEGF would improve
contractility in the scar and decrease the LV dimension, or was it
just to precondition the heart for the injection of the cells?
Dr Chachques. All the groups that have worked with angio-
genic growth factors for myocardial infarction, including your
group, have tried to demonstrate that angiogenic growth factors
could improve both vascularization and myocardial function. In
this direction, we tried to investigate whether angiogenic growth
factors associated or not with cellular therapy would improve
myocardial function. In our study, we demonstrated angiogenesis
only in myocardial infarcts treated with VEGF. We think that in
the future, the best way for functional improvement will be a
2-step procedure: first, angiogenesis induction, and second, cellu-
lar therapy. Angiogenic growth factors could be delivered by
endoventricular catheters, and then, in a second step, the cells
could be surgically implanted.
Dr Masashi Komeda (Kyoto, Japan). As you said, the 2-step
application of angiogenesis factors is very useful. We presented
that result at the American Heart Association meeting a couple of
years ago when we used the basic fibroblast growth factor slow
release, not just direct injection, in advance—1 week before cell
transplantation. The result was a lot better, in terms of both
function and angiogenesis. I will bet that if you use either gene
therapy or slow release, particularly in advance, the result will be
different. We see a lot more angiogenesis, not 20% more but 50%
more or 80% more, and even the function is better.
Dr Chachques. We tried to perform our protocol in only one
surgical procedure to avoid the risk of reoperations in animals with
heart failure. The best approach would be a 2-step procedure.
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PDr Terrence M. Yau (Toronto, Ontario, Canada). I notice that
you did not see any evidence of angiogenesis in this preparation,
although transplantation of a number of cell types has been de-
scribed to induce at least modest angiogenesis in a variety of other
models. Have you looked at microspheres or any other evaluation
of regional blood flow?
Also, I see that you colocalized your growth factors and your
cell therapy by putting the growth factors in the suspended me-
dium, but have you tried looking at either depot protein therapy or
transfecting your cells with angiogenic growth factors to try to
prolong the expression of those growth factors? We have previ-
ously reported that transplantation of cells transfected with VEGF
can dramatically increase the degree of local angiogenesis in a
myocardial scar, and we believe that this combination may be
potentially therapeutically useful.
Dr Chachques. The goal of our study was to develop a safe
therapeutic approach for heart failure that can be easily reproduced
by cardiac surgeons. For this reason, we used growth factors in the
form of proteins associated or not with intramyocardial cell im-
plantation. This combined procedure could be improved according
to your remarks.
Dr Sidney Levitsky (Boston, Mass). Do you have any evi-
dence from studying the postmortem specimens concerning the
viability of the cells that you implanted? Is there any relationship
of the volume of cells that survived and the postoperative ejection
fraction? Were you able to see any correlation, or is this just an
all-or-nothing phenomenon?
Dr Chachques. The immunohistologic study that I showed
demonstrated viable cells that were reactive against specific anti-
bodies. We did not quantify the cells identified in histologic slides.
It is important to remark that one of the main goals of cell therapy
is to transform the fibrotic infarcted scar into living tissue. The
transplanted cells can be organized into the myocardium in myo-
tubes and myofibers. This configuration is appropriate for cardiac
remodeling. The elasticity of the ventricular wall can be improved,
and the size of the scar can be reduced. I think that this is very
positive, because in ischemic cardiomyopathies, one of the most
important problems is the ventricular remodeling process, which
can be stabilized or reversed by this cellular organization.
Dr Georg Lutter (Freiburg, Germany). Very interesting paper,
Dr Chachques. First, I would like to know whether you analyzed
your area at risk and infarction area. Second, I am wondering why
you used VEGF as a growth factor, because it is known to induce
angiogenesis, and whether what you need long-term and in a
chronic model is arteriogenesis, for instance, induced by fibroblast
The Journal of Thoracigrowth factor. We have already used fibroblast growth factor 1 in
humans, and we have seen good angiogenesis and maybe also
arteriogenesis. Could you explain why you chose VEGF and not,
for instance, granulocyte macrophage colony-stimulating factor or
fibroblast growth factor?
Dr Chachques. We tried to demonstrate in this study that new
biologic procedures for myocardial diseases can be positively
associated. We started using VEGF, but we think that it is a very
interesting idea to also use basic fibroblast growth factor or other
growth factors, because basic fibroblast growth factor also has the
possibility to induce myogenesis and not only angiogenesis. These
properties are very important for the future of cellular cardiomy-
oplasty.
Concerning the study of the diseased area, macroscopically it is
very difficult to find which area must be selected for histologic
evaluation. Furthermore, in our study we evaluated the size of the
ventricular infarction to demonstrate the reduction of the size of
the scar.
Dr Hikaru Matsuda (Osaka, Japan). We have been conduct-
ing a similar study of transfecting angiogenic growth factor to the
ischemic myocardium. Instead of VEGF, we used hepatocyte
growth factor, and the difference compared with your study is
striking. Namely, the combined therapy with hepatocyte growth
factor and cell transplantation showed apparently better results in
function than those with the single therapy (cell transplantation or
growth factor). My question is this: what did you expect the
survivals of the cells to be in the cell transplantation alone group
compared with the combined group? We have assumed that the
growth factor may have a role in giving the blood supply to
implanted cells, thus providing better survival and subsequent
functional improvements.
Dr Chachques. One of the points that must be studied in the
future is the quantification of the number of cells, not only before
implantation but mainly after implantation (rate of cell survival).
This was not performed in this study. The histologic samples that
we analyzed seemed to show that the number of viable cells did
not improve with the simultaneous combination of angiogenic
growth factors. This was observed in our qualitative analysis.
I also want to comment that in the past, we associated electro-
stimulation with cell therapy to induce contractility of infarcted
areas, because skeletal myoblasts do not contract spontaneously
after myocardial implantation. In the future, the combination of
cell therapy, angiogenesis, and electrostimulation could be a better
approach for myocardial ischemic disease.
c and Cardiovascular Surgery ● Volume 128, Number 2 253
